Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Aeterna Zentaris's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AEZS is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: AEZS's weekly volatility has decreased from 32% to 11% over the past year.
7 Day Return
1 Year Return
Return vs Industry: AEZS exceeded the Canadian Biotechs industry which returned -8.9% over the past year.
Return vs Market: AEZS exceeded the Canadian Market which returned 29% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Aeterna Zentaris's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHere's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation
2 months ago | Simply Wall StIf You Had Bought Aeterna Zentaris' (TSE:AEZS) Shares Five Years Ago You Would Be Down 77%
Is Aeterna Zentaris undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AEZS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AEZS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AEZS is unprofitable, so we can't compare its PE Ratio to the North American Biotechs industry average.
PE vs Market: AEZS is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AEZS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AEZS is good value based on its PB Ratio (1.4x) compared to the CA Biotechs industry average (3.4x).
How is Aeterna Zentaris forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aeterna Zentaris has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Aeterna Zentaris performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AEZS is currently unprofitable.
Growing Profit Margin: AEZS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AEZS is unprofitable, but has reduced losses over the past 5 years at a rate of 44.7% per year.
Accelerating Growth: Unable to compare AEZS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AEZS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (32.6%).
Return on Equity
High ROE: AEZS has a negative Return on Equity (-11.44%), as it is currently unprofitable.
How is Aeterna Zentaris's financial position?
Financial Position Analysis
Short Term Liabilities: AEZS's short term assets ($77.6M) exceed its short term liabilities ($4.9M).
Long Term Liabilities: AEZS's short term assets ($77.6M) exceed its long term liabilities ($17.9M).
Debt to Equity History and Analysis
Debt Level: AEZS is debt free.
Reducing Debt: AEZS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AEZS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AEZS has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 32% each year
What is Aeterna Zentaris's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AEZS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AEZS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AEZS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AEZS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AEZS's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Klaus Paulini, PhD, has been President, Chief Executive Officer and Executive Director of Aeterna Zentaris Inc., since October 4, 2019. Dr. Paulini has been Managing Director at Aeterna Zentaris GmbH s...
CEO Compensation Analysis
Compensation vs Market: Klaus's total compensation ($USD792.15K) is above average for companies of similar size in the Canadian market ($USD165.99K).
Compensation vs Earnings: Klaus's compensation has increased whilst the company is unprofitable.
Experienced Management: AEZS's management team is considered experienced (2.3 years average tenure).
Experienced Board: AEZS's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 413.7%.
Aeterna Zentaris Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aeterna Zentaris Inc.
- Ticker: AEZS
- Exchange: TSX
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$111.461m
- Shares outstanding: 121.15m
- Website: https://www.zentaris.com
Number of Employees
- Aeterna Zentaris Inc.
- 315 Sigma Drive
- South Carolina
- United States
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/01 22:16|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.